創薬における環状ペプチドのトレンドと治療の方向性

Join a panel of CAS scientists and pharma experts to see where cyclic peptide research is going, what is driving the push toward oral dosing, and what it takes to carry a macrocyclic peptide from a promising binder to an FDA-approved drug.

本ウェビナーの内容：

• Where cyclic peptide research is concentrating, drawn from a CAS Insights™ analysis of 46,574 cyclic peptides indexed in the CAS Content Collection™ for 2020 to 2025, including the point in 2023 when patent publications overtook journal articles.

• Which structural choices recur in the molecules being pursued for oral delivery. Macrocyclic scaffolds account for more than half the set and head-to-tail cyclization for roughly two-thirds. N-methylation is the most common modification.

• What the path of enlicitide (MK-0616), the oral PCSK9-inhibiting cyclic peptide from Merck, approved by the FDA in July 2026, shows about moving this modality from discovery through process development and into the clinic.

Whether the work is designing new macrocycles, weighing the modality against a target that has resisted small molecules, or planning how to make one at scale, the session gives a clear view of where cyclic peptides stand and what the next few years are likely to bring.